Atlas Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

Clinical trial NCT07717905 · RECRUITING

Trial details

NCT number
NCT07717905
Sponsor
Bambusa Therapeutics
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Chronic Spontaneous Urticaria
Start date
2026-06-29
Primary completion
2027-12-31
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.